StockNews.com began coverage on shares of Invitae (NYSE:NVTA – Free Report) in a research report report published on Friday morning. The brokerage issued a hold rating on the medical research company’s stock. Separately, The Goldman Sachs Group decreased their price objective on Invitae from $1.00 to $0.50 and set a sell rating for the company […]